In addition, the Myc family member N-Myc has been shown to be amplified in neuroblastoma and lung cancer, and our dimeric inhibitors would be expected to have activity versus N-Myc as well as Myc due to the high homology between their bHLHZip domains. Here, MYC is linked to lung cancer.